611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
New Hormonal Pill May Boost Outcomes for Older Breast Cancer PatientsHad COVID? Getting Vaccinated Strengthens Your Antibodies to New VariantsU.S. to Pump $400 Million Into Vaccination Programs for Other CountriesPandemic Sent Americans' Blood Pressure Numbers SkywardWere Cancer Patients Neglected in U.S. COVID Vaccine Rollout?Young People Recover Quickly From Rare Heart Side Effect of COVID VaccineMore Evidence That Pandemic Delayed Cancer DiagnosesHigh Heart Rate Linked to Dementia RiskCOVID Vaccine, Testing Demand Overwhelming PharmaciesOmicron Spreading Through Africa Twice as Fast as Delta DidWith Holidays Ahead, COVID Boosters a Must for People With Weak Immune SystemsKeep Your Holidays Allergy-Free This YearDo Immune-Based Cancer Drugs Work Better in Men?Gene Found in Amish Helps Protect Their HeartsOmicron May Overcome Prior COVID InfectionWindy Days Are Safer Days When It Comes to COVID-19Most Vaccinated Adults Plan to Get Boosters: PollStudy Finds Delta Somewhat Resistant to Vaccines — What About Omicron?Is the Mumps Vaccine Becoming Less Effective?Vaping Can Trigger Gene Changes in Cells: StudyPfizer or Moderna? Head-to-Head Study Shows One Shot Has an EdgeSurvivors of Severe COVID Face Doubled Risk for Death a Year LaterKids With Uncontrolled Asthma at Higher Odds for Severe COVID-19Nearly 7% of U.S. Kids Have Had a Head Injury or ConcussionFirst U.S. Omicron Case Reported in California'Ultra-Processed' Foods Up Odds for a Second Heart Attack or StrokeCDC to Toughen COVID Testing for International TravelersAHA News: Irregular Heartbeat Risk Linked to Frequent Alcohol Use in People Under 40Certain Blood Thinners Can Raise Risk of 'Delayed' Bleeding After Head InjuryFDA Panel Gives Support to Merck's COVID Antiviral PillLong-Haul COVID Can Include Chronic Fatigue: StudyVaccines, Boosters Should Protect Against Severe COVID, Even With Omicron: FauciPfizer to Seek FDA Approval of Boosters for Teens Ages 16-17Regeneron Says Its Antibody Cocktail Likely Weakened by Omicron VariantCOVID May Trigger Heart Condition in Young AthletesMany People With High Blood Pressure May Take a Drug That Worsens It: StudyBiden Pushes Vaccines, Masks as Best Defense Against Omicron VariantHow Easily Can Singing Spread COVID-19?New Insights Into What Might Drive Parkinson's DiseaseHot Days Can Send Even Younger Folks to the ERRed Light in Morning May Protect Fading Eyesight: StudyMerck's COVID Pill Appears Effective, But May Pose Pregnancy Risks: FDAVaccine Makers Already Testing Their Shots Against Omicron VariantWhat Experts Know About the Omicron 'Variant of Concern'Gout Drug Colchicine Won't Help Fight COVID-19What You Need to Know About Stomach CancerFetal Infection With COVID-19 Possible, But UnlikelyCOVID Protection Wanes After 2 Doses of Pfizer Vaccine: StudyRural Hospitals' ERs Just as Effective as Urban Ones: Study1 in 5 Avoided Health Care During Pandemic, Study Finds
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

People on Immune-Suppressing Meds Fare Equally Well With Severe COVID

HealthDay News
by Robert Preidt
Updated: Nov 22nd 2021

new article illustration

MONDAY, Nov. 22, 2021 (HealthDay News) -- Hospitalized COVID-19 patients who take medications that suppress the immune system don't have a higher risk of severe COVID-19 than those with normal immune systems, a new study finds.

Early in the pandemic, it was feared that people taking immunosuppressive drugs were at increased risk of severe COVID-19 due to their weakened immune systems. The drugs are used to treat cancer and autoimmune diseases, and to prevent transplant rejection, for instance.

"In general, people taking immunosuppressive medications may be reassured that they can safely continue to do so during this pandemic," said lead author Kayte Andersen, a doctoral candidate at Johns Hopkins Bloomberg School of Public Health, in Baltimore.

To learn more, her team analyzed data from nearly 222,600 U.S. adults hospitalized with COVID-19 from January 2020 to June 2021. Of those, 7% were taking immunosuppressive drugs before hospitalization.

The investigators separated the immunosuppressive medications into 17 classes and found that none was associated with a significantly higher risk of being put on a ventilator, an indication of severe COVID-19 illness.

The findings were published online Nov. 15 in The Lancet Rheumatology journal.

"These findings are encouraging and important, given how commonly these medications are used," said study co-author G. Caleb Alexander, a professor of epidemiology at Johns Hopkins.

The researchers did link one drug, rituximab, with a substantially increased risk of death. The drug is given to patients with serious medical conditions like cancer or an autoimmune disorder that has not responded to other treatments.

"Given the finding, patients taking rituximab should discuss their options with their doctor," Andersen said in a Hopkins news release. "At a minimum, people who take rituximab should continue to protect themselves from developing COVID-19. It also makes it all the more important that people around those taking rituximab get vaccinated."

The researchers also found that a relatively new class of immunosuppressive drugs called JAK inhibitors — used to treat arthritis, inflammatory bowel disease and other inflammatory conditions — were associated with a 58% lower risk of COVID-related in-hospital death.

JAK inhibitors such as baricitinib have recently been used to treat severe COVID-19, the researchers noted.

More information

The U.S. National Cancer Institute has more on immunotherapy for cancer.

SOURCE: Johns Hopkins Bloomberg School of Public Health, news release, Nov. 16, 2021